GlassScriptPhysician profile
Rafael Gerald Basa
NPI 1528831948
$3,341.40
in general payments reported to CMS, 2019-2025
25 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,088 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,341.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $592.62 | 2024-2025 | Fintepla, Briviact |
| Abbvie INC. | $547.86 | 2024-2025 | |
| Eisai INC. | $362.64 | 2025 | |
| Lundbeck LLC | $234.16 | 2024-2025 | Vyepti |
| Lilly USA, LLC | $223.75 | 2024-2025 | Kisunla, Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $223.09 | 2024-2025 | Hyqvia |
| Boston Scientific Corporation | $172.21 | 2025 | Wavewriter Alpha Prime 16, Infinion 16 |
| Biotronik Nro, INC. | $155.89 | 2025 | Prospera |
| Argenx US, INC. | $115.95 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Azurity Pharmaceuticals, INC. | $98.50 | 2024 | Horizant |
| Merz Pharmaceuticals, LLC | $92.85 | 2024 | Xeomin |
| Saluda Medical Americas, INC. | $81.23 | 2025 | Evoke |
| Novartis Pharmaceuticals Corporation | $75.16 | 2024-2025 | |
| Grifols USA, LLC | $72.86 | 2024-2025 | Gamunex-C |
| Averitas Pharma INC. | $57.74 | 2025 | Qutenza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.67 | 2025 | Relistor |
| Catalyst Pharmaceuticals, INC. | $41.33 | 2024-2025 | |
| Globus Medical, INC. | $24.19 | 2025 | Senza |
| Amneal Pharmaceuticals LLC | $20.73 | 2025 | Brekiya |
| Life Molecular Imaging LTD | $18.65 | 2025 | Neuraceq |
| Tersera Therapeutics LLC | $18.60 | 2025 | Prialt |
| Biogen, INC. | $18.43 | 2025 | Spinraza |
| Impel Pharmaceuticals LLC | $18.11 | 2025 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $17.50 | 2025 | Rexulti |
| Tonix Medicines, INC. | $14.68 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Basa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.